« Back
Home /
Daunorubicin (hydrochloride)

Daunorubicin (hydrochloride)

Item no.	HY-13062-5mg
Manufacturer	MedChem Express
CASRN	23541-50-6
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 25 mg 500 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.67
Citations	[1]Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7.\|[2]Svensson SP, et al. Melanin inhibits cytotoxic effects of Doxorubicin and Daunorubicin in MOLT 4 cells. Pigment Cell Res. 2003 Aug;16(4):351-4\|[3]Gervasoni JE Jr, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and Daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26\|[4]Arozal W, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions. Toxicology. 2011 Jan 11;279(1-3):91-9.\|[5]Dano K, et al. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res. 1972 Jun;32(6):1307-14.\|[6]Emeline Bollaert, et al. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin. Int J Mol Sci. 2021 May 13;22(10):5153. \|[7]Cheng Wu, et al. Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. Eur J Pharm Sci. 2021 Dec 1;167:106013. ACS Nano. 2024 Nov 1.\|bioRxiv. 2023 Jan 13.\|Cancers (Basel). 2021, 13(5), 1127.\|Cell Mol Immunol. 2023 Jan;20(1):51-64.\|Cell Signal. 2025 Jan 24:111625.\|Cell Signal. 2025 Mar 11:111735.\|Curr Pharm Anal. 2018 Jan, 14(1):53-59(7).\|Front Biosci (Landmark Ed). 2024 Oct 21;29(10):362.\|Front Genet. 05 August 2021.\|J Control Release. 2022 Apr 22;346:136-147.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|J Transl Med. 2022 Jul 6;20(1):304.\|Life Sci. 2024 Dec 5:123297.\|Mol Cell Biochem. 2021 Feb;476(2):1233-1243.\|Patent. US20240319170A1\|Pharmaceutics. 2021, 13(5), 661.\|ACS Infect Dis. 2022 Jul 19.\|bioRxiv. 2024 July 04.\|Cancer Biol Ther. 2020 Apr 2;21(4):320-331.\|Cancer Res. 2023 Dec 14.\|Cancers (Basel). 2022 Oct 19;14(20):5127.\|Cell Oncol. 2022 Aug 29.\|Clin Cancer Res. 2020 Apr 15;26(8):2011-2021. \|Front Oncol. 2021 Apr 22;11:665763.\|Front Oncol. 2021 Apr 6.\|Leukemia. 2023 Mar 28.\|Microb Drug Resist. 2020 Jan;26(1):81-88.\|Oncol Lett. 2020 Jan;19(1):368-378.\|Universidad De Salamanca. 2023
Smiles	O=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Daunomycin (hydrochloride),RP 13057 (hydrochloride),Rubidomycin (hydrochloride)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	ADC Payload; Antibiotic; Apoptosis; Autophagy; Bacterial; DNA/RNA Synthesis; Topoisomerase
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	563.98
Product Description	Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5].
Manufacturer - Research Area	Cancer; Infection; Neurological Disease
Solubility	DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O : ≥ 34 mg/mL
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage
Clinical information	Launched
Isoform	Daunorubicins/Doxorubicins; Topo II

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.